[250 Pages Report] The nephrology and urology incontinence devices market is expected to record a CAGR of 4.1% during the forecast period, up from US$ 38 Billion in 2021 to reach a valuation of US$ 46.4 Billion by 2026.
| Report Attributes | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 38 Billion |
| Anticipated Forecast Value (2026) | US$ 46.4 Billion |
| Projected Growth Rate (2022 to 2032) | 4.1% CAGR |
Sales of nephrology and urology incontinence devices are expected to rise due to government measures to support R&D in the field.
For instance, during the virtual KidneyX Summit in July 2020, the United States Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) revealed the six winners of the US$ 3 million KidneyX: Redesign Dialysis Phase 2 competition.
In addition to this, demand for nephrology and urology incontinence devices has also increased due to the focused concentration on providing digital solutions during the Covid-19 pandemic.
The global nephrology and urology devices market is predicted to increase due to the increasing geriatric population.
The sales of nephrology and urology incontinence devices are projected to be hampered by high installation costs for equipment such as lithotripters and sophisticated machines and further projected to contribute to the growth of nephrology and urology incontinence devices market share.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Presently, the sales of nephrology and urology incontinent devices are primarily driven by the rising prevalence of chronic kidney disease (CKD), Benign Prostatic Hyperplasia (BPH) and End Stage Renal Disease (ESRD).
Growing awareness programs about these particular diseases and personal hygiene among patients will result in the increased demand for nephrology and urology incontinent devices in the forecast years.
Also, with the increase in healthcare expenditure and favorable reimbursement in the developed countries, the sales of nephrology and urology incontinent devices are expected to have a healthy growth.
Rising incidence rates and health consequences of urological disorders result in the growing demand for nephrology and urology incontinence devices treatments to manage them, boosting the sales of neurology and urology incontinence devices.
Principal Consultant
Depending on geographic regions, the nephrology and urology incontinence devices market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
North America and Europe are expected to capture the most significant sales of nephrology and urology incontinence devices, followed by Asia Pacific countries where the demand for nephrology and urology incontinence devices market is expected to grow due to increased awareness of personal hygiene and an increase in disposable income of middle-class consumers.
Some of the key participating players in the nephrology and urology incontinence devices market are Baxter International Inc., C. R. Bard, Inc, Coloplast UK Ltd., Unicharm Corporation., Kimberly-Clark Corporation, Hollister Inc., ConvaTec, B.Braun Melsungen AG, SCA (Svenska Cellulosa Aktiebolaget) and others.
Increased demand for nephrology and urology incontinence devices is predicted to rise due to a growing desire for minimally invasive and non-invasive treatment approaches.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.1% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Regions Covered | North America; Latin America; Europe; APAC; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Mexico, Brazil, Germany, Italy, France, UK, Spain, China, India, Japan, Australia, South Korea, ASEAN, GCC, Israel, South Africa, Central Africa |
| Key Companies Profiled | Baxter International Inc.; C. R. Bard, Inc.; Coloplast UK Ltd.; Unicharm Corporation; Kimerly-Clark Corporation; Hollister Inc.; ConvaTec; B.Braun Melsungen AG; SCA (Svenska Cellulosa Aktiebolaget) |
| Customization Scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The nephrology and urology incontinence devices market are predicted to register a CAGR of 4.1% during the forecast period.
Key players holding substantial nephrology and urology incontinence devices market share includes Baxter International Inc., C. R. Bard, Inc, Coloplast UK Ltd., Unicharm Corporation., Kimerly-Clark Corporation, Hollister Inc., ConvaTec, B.Braun Melsungen AG, SCA (Svenska Cellulosa Aktiebolaget) and others.
As per the analysis, the nephrology and urology incontinence devices market share are likely to be US$ 46.4 Bn by 2026.
Demand for nephrology and urology incontinence devices market is likely to rise on the back of increasing due to the focused concentration on providing digital solutions during Covid-19 pandemic and the increasing geriatric population.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Bn) Analysis By Product Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Product Type, 2022-2032 5.3.1. Penile Compression Device 5.3.2. Pessary 5.3.3. Urethral Insert 5.3.4. Artificial Urinary Sphincter 5.3.5. Bladder Neck Support Device 5.3.6. Urine Seal 5.3.7. Absorbent Products 5.3.8. Catheters 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Bn) Analysis By Type, 2017-2021 6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Type, 2022-2032 6.3.1. Stress Incontinence 6.3.2. Urge incontinence 6.3.3. Overflow Incontinence 6.3.4. Functional Incontinence 6.3.5. Mixed Incontinence 6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021 6.5. Absolute $ Opportunity Analysis By Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Homecare Settings 7.3.4. Nursing Homes 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request 8. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.K. 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Type 10.3.4. By End User 10.4. Key Takeaways 11. Europe Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Product Type 11.2.3. By Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Type 11.3.4. By End User 11.4. Key Takeaways 12. East Asia Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Product Type 12.2.3. By Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Type 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Thailand 13.2.1.3. Indonesia 13.2.1.4. Malaysia 13.2.1.5. Singapore 13.2.1.6. Australia 13.2.1.7. New Zealand 13.2.1.8. Rest of South Asia & Pacific 13.2.2. By Product Type 13.2.3. By Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Type 13.3.4. By End User 13.4. Key Takeaways 14. MEA Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Product Type 14.2.3. By Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Type 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Nephrology and Urology Incontinence Devices Market Analysis 15.1. U.K. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Product Type 15.1.2.2. By Type 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Product Type 15.2.2.2. By Type 15.2.2.3. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Product Type 15.3.2.2. By Type 15.3.2.3. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Product Type 15.4.2.2. By Type 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Product Type 15.5.2.2. By Type 15.5.2.3. By End User 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Product Type 15.6.2.2. By Type 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Product Type 15.7.2.2. By Type 15.7.2.3. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Product Type 15.8.2.2. By Type 15.8.2.3. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Product Type 15.9.2.2. By Type 15.9.2.3. By End User 15.10. China 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Product Type 15.10.2.2. By Type 15.10.2.3. By End User 15.11. Japan 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Product Type 15.11.2.2. By Type 15.11.2.3. By End User 15.12. South Korea 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Product Type 15.12.2.2. By Type 15.12.2.3. By End User 15.13. India 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Product Type 15.13.2.2. By Type 15.13.2.3. By End User 15.14. Thailand 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Product Type 15.14.2.2. By Type 15.14.2.3. By End User 15.15. Indonesia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Product Type 15.15.2.2. By Type 15.15.2.3. By End User 15.16. Malaysia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Product Type 15.16.2.2. By Type 15.16.2.3. By End User 15.17. Singapore 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Product Type 15.17.2.2. By Type 15.17.2.3. By End User 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Product Type 15.18.2.2. By Type 15.18.2.3. By End User 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Product Type 15.19.2.2. By Type 15.19.2.3. By End User 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Product Type 15.20.2.2. By Type 15.20.2.3. By End User 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2021 15.21.2.1. By Product Type 15.21.2.2. By Type 15.21.2.3. By End User 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2021 15.22.2.1. By Product Type 15.22.2.2. By Type 15.22.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product Type 16.3.3. By Type 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Becton, Dickinson and Company 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. UROMED Kurt Drews KG 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Stryker Corporation 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. B. Braun Melsungen AG 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Boston Scientific Corporation 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Cook Medical LLC 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. CooperSurgical, Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Medgyn Products, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Bioderm Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Thomas Medical, Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Essity Hygiene and Health AB 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. ZEPHYR SURGICAL IMPLANTS SÀRL 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.13. Coloplast Corp. 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.14. Femeda Ltd. 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.15. Domtar Corporation 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Nephrology and Urology Incontinence Devices Market
